COVID-19 Precipitating Euglycaemic Diabetic Ketoacidosis with SGLT2 Inhibitor Use
  • Jiali Fang
    Department of Medicine, University of Illinois at Chicago, Chicago, USA
  • Matthew Genco
    Department of Medicine, University of Illinois at Chicago, Chicago, USA
  • Rachel Caskey
    Department of Medicine, University of Illinois at Chicago, Chicago, USA

Abstract

Objective: To describe a patient who developed euglycaemic diabetic ketoacidosis (DKA) in the setting of SGLT2 inhibitor use precipitated by COVID-19.
Patient and methods: A 52-year-old male with type II diabetes on empagliflozin and no history of DKA presented with symptoms of COVID-19 as well as laboratory findings consistent with euglycaemic DKA. His hospital course was complicated by recurrent episodes of euglycaemic DKA as well as hyperglycaemic DKA. 
Conclusion: SGLT2 inhibitors should be held as early as possible in COVID-19 cases due to the risk of euglycaemic DKA. These patients should also have more intense glucose monitoring.

VIEW THE ENTIRE ARTICLE

References

  • Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 2016;38(12):2654–2664.e1.
  • Bornstein SR, Rubino F, Khunti K, Mingrone G, Hopkins D, Birkenfeld AL, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 2020;8(6):546–550.
  • Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020;22:1935–1941.
  • Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2014;53(3):213–225.
  • Fernandez-Fernandez B, D’Marco L, Górriz JL, Jacobs-Cachá C, Kanbay M, Luis-Lima S, et al. Exploring sodium glucose co-transporter-2 (SGLT2) inhibitors for organ protection in COVID-19. J Clin Med 2020;9(7):2030.
  • Views: 1141
    HTML downloads: 82
    PDF downloads: 591


    Published: 2020-10-26
    Issue: 2020: Vol 7 No 11 (view)


    How to cite:
    1.
    Fang J, Genco M, Caskey R. COVID-19 Precipitating Euglycaemic Diabetic Ketoacidosis with SGLT2 Inhibitor Use. EJCRIM 2020;7 doi:10.12890/2020_001943.